“People with dementia living in nursing homes and in the community were prescribed less and we did not detect negative health impacts for these groups.”
LEQEMBI® is the newest Alzheimer’s drug. It is administered in hospitals via IV. Biogen applied to the FDA for approval of a home version using an “Autoinjector”. See how it works and learn its advantages.
The first doses of the newly approved Alzheimer’s drug “Leqembi” were administered in Louisville. More than 100 people have signed up since then. See why.
Biogen reprioritize resources allocated to ADUHELM® to advance LEQEMBI®.
At long last, we finally have a disease-modifying drug for Alzheimer’s. The FDA recently approved a new drug that promises to slow the progression of the disease. Only five Alzheimer’s treatments have been approved by the FDA up until a decade ago, and this is only the second to address the progression of the disease.
FDA-approved ADLARITY is the once-weekly donepezil patch. See how it compares to donepezil / Aricept / Ebixa tablets for Alzheimer’s.
A neuroradiologist at the Mayo Clinic in Jacksonville, FL warns that increased use of monoclonal antibody treatment for Alzheimer’s has also led to the discovery of amyloid-related imaging abnormalities — ARIA. Find out more.
The first drugs for Alzheimer’s disease emerged in the 1990s, but since then there has been a wave of clinical trial failures, major companies pulling resources from neuroscience R&D, and progress.
Dr. Robert Przybelski has prescribed lecanemab to real-life patients, and discusses his experience prescribing and administering the treatment.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
A personal diary of a daughter with a medical background that chronicles her journey while caring for her father with Alzheimer’s, and gives the reader the gift of both perspectives, that of a loving daughter and the trained professional.
Scientists say restoring a brain protein, not removing amyloid plaques, should be the target of Alzheimer’s dementia therapies. The researchers said treatment might lie in normalizing the levels of a specific brain protein.
Did you know? Intellectual abilities are increased in the brain by an average 300% in most people ages 60-80.
The brush strokes are precise, the colors vibrant. See a Colorado art program help patients rise above dementia, while the paintings raise money for The Alzheimer’s Association.
The protein BDNF builds synapses in the human brain, nurturing brain cells and fighting off dementia. While there is no artificial way of boosting it, social and cognitive activity can.
People may not have easy access to sophisticated, expensive dementia tests. A simple test from Einstein Medicine uses a stopwatch and a few questions to determine one’s risk of dementia. The potential payoff could be tremendous for individuals, their families and society.
Ketone-rich diets increase the SIRT3 protein that protects neurons from death during the progression of Alzheimer’s disease. But how does it work? Find out more.
No spam, only news and updates.
